Key Milestones2 |
|
---|---|
Call for patient input posted | August 28, 2019 |
Patient group input closed | October 18, 2019 |
Clarification:
- Patient input submission received from Canadian Council of the Blind, CNIB Foundation, Fighting Blindness Canada, Vision Loss Rehabilitation Canada (Joint Submission) |
|
Patient input summary sent for review to patient input groups | December 04, 2019 |
Patient group comments on input summary closed | December 11, 2019 |
Clarification:
- No patient input summary feedback received |
|
Submission received | September 26, 2019 |
Submission accepted | November 28, 2019 |
Clarification:
- Submission was not accepted for review on 10-Oct-2019 - Revised category 1 requirements received on 25-Nov-2019 |
|
Review initiated | November 29, 2019 |
Draft Canada's Drug Agency review report(s) sent to sponsor | February 20, 2020 |
Comments from sponsor on draft Canada's Drug Agency review report(s) received | March 02, 2020 |
Canada's Drug Agency review team's comments on draft Canada's Drug Agency review report(s) sent to sponsor | April 02, 2020 |
Canadian Drug Expert Committee (CDEC) meeting | April 15, 2020 |
CDEC recommendation sent to sponsor and drug plans | April 29, 2020 |
Embargo period ended | May 13, 2020 |
CDEC Final Recommendation & Canada's Drug Agency review report(s) issued to sponsor and drug plans | May 21, 2020 |
CDEC Final Recommendation posted | May 25, 2020 |
Redaction requests from sponsor on draft Canada's Drug Agency review report(s) received | June 04, 2020 |
Clarification:
- No redactions requested by the sponsor |
|
Final Canada's Drug Agency review report(s) posted | July 03, 2020 |
Osteoporosis is a systemic skeletal disease characterized by a loss of bone mass and an increased risk of fragility fractures. Osteoporosis is highly prevalent, affecting an estimated 1.5 million Canadians over 40 years of age. Fractures associated with osteoporosis commonly occur in vertebral sites, but also occur in non-vertebral sites. They are associated with significant costs, diminished quality of life, and mortality, as well as an increased risk of future fractures.
As the population ages, decision-makers are faced with different choices of care models for people diagnosed with dementia. Recent media reports have focused on dementia villages, first developed at de Hogeweyk in the Netherlands. This Horizon Scanning bulletin will present a narrative review of the literature describing elements of care, as well as evidence and issues concerning dementia villages and similar models or components of care. Stakeholder perspectives and an analysis of policy issues will also be incorporated.